Biomarker allows for cost-effective throat cancer imaging, study suggests

07/25/2013 | Medscape (free registration)

A study published in the Journal of Clinical Oncology found risk stratification using plasma Epstein-Barr virus DNA levels helps determine the utility of PET/CT for finding metastases in nasopharyngeal carcinoma. Chinese researchers conducted PET/CT imaging plus MRI and a clinical workup with chest X-ray, abdominal ultrasound and skeletal scintigraphy in 583  patients. After the evaluation of findings, researchers recommended only clinical workup for very low-risk patients, a choice between clinical workup or imaging for low-risk patients and PET/CT for intermediate-risk patients. PET/CT led to a change in treatment plans for 16.5% of the intermediate-risk patients.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI